Vaskulárna medicína 1/2019
Laboratory monitoring of direct oral anticoagulants
The direct oral anticoagulants (DOAC) represent a new generation of antithrombotic agents, providing direct inhibition of either thrombin (factor IIa; FIIa) or activated factor X (FXa). This narrative review aims to briefly summarise the evidence concerning utility of different laboratory assays for qualitative and quantitative assessment of DOAC and ultimately discussing advantages and limitations of these processes in clinical practice.
Keywords: direct oral anticoagulants, dabigatran, rivaroxaban, apixaban, edoxaban, laboratory monitoring
